From: Age estimation using DNA methylation technique in forensics: a systematic review
Reference and year | Population | Source of samples | Age range (years) | Sample size | CpG coverage | Genes | Technique/†gDNA | Statistical model | Age prediction (MAD) |
---|---|---|---|---|---|---|---|---|---|
Weidner et al. 2014 | Germany | Blood | 20–75 | 151 samples | 3 CpGs | ASPA, ITGA2B, PDE4C | Pyrosequencing/ 500 ng | MLRM | 5.43 |
Chinese | Blood | 20–80 | 49 healthy females | 6 CpGs | ADAR, AQP11, ITGA2B, PDE4C | EpiTYPER/ 1 μ | SVRM | 2.8 | |
Polish | Blood | 2–75 | 300 male females | 5 CpGs | ELOVL2, C1orf132, TRIM59, KLF14, FHL2 | Pyrosequencing/ 2 μg | MLRM | 3.4 | |
Freire-Aradas et al. 2016 | European | Blood | 18–104 | 725 male females | 7 CpGs | ELOVL2, ASPA, PDE4C, FHL2, CCDC102B, C1orf132, chr16:85395429 | EpiTYPER/ 300 ng | MQTRM | MAE ± 3.07 |
Park et al. 2016 | Korean | Blood | 11–90 | 535 samples | 3 CpGs | ELOVL2, ZNF423, CCDC102B | Pyrosequencing/ 500 ng | MLRM | ± 3.34 |
Hamano et al. 2016 | Japanese | Blood | 0–95 | 22 healthy individuals, 52 cadavers | 24 CpGs | ELOVL2, FHL2 | MS-HRM/ NA | MLRM | 7.44 |
Zubakov et al. 2016 | Germany | Blood | 4–82 | 216 healthy males | 8 CpGs | ELOVL2, FHL2 | EpiTYPER/ 500 ng | MLRM | 4.22 |
Cho et al. 2017 | Korean | Blood | 20–74 | 100 healthy male females | 5-13 CpGs | ELOVL2, C1orf132, TRIM59, KLF14, FHL2 | Pyrosequencing/ 500 ng | MLRM | 4.18 |
Naue et al. 2017 | Netherlands | Blood | 18–69 | 208 samples | 13 CpGs | ELOVL2, TRIM59, F5, KLF14, DDO, GRM2, HOXC4, LDB2, MEIS1-AS3, NKIRAS2, RPA2, SAMD10, ZYG11A | MPS, Sanger sequencing/ 300 ng | RFR | 3.24 |
Freire-Aradas et al. 2018 | European | Blood | 2–18 | 209 healthy donors | 6 CpGs | FLJ40365, SDS, PGLYRP2, EDARADD, HKR1, KCNAB3, PRKG2, FLJ46365, ITGA2B, TOM1L1 | EpiTYPER/ 300 ng | MQTRM | MAE ±0.94 |
Feng et al. 2018 | Chinese Han | Blood | 15–75 | 390 males | 9 CpGs | ELOVL2, PDE4C, C1orf132, CCDC102 B, RASSF5, TRIM59, cg10804656 | Pyrosequencing EpiTYPER/ 1 μg | MLRM, SVRM, ANN | 2.89 |
Spolnicka et al. 2018 | Polish | Blood | 12–76 | 120 healthy, 190 with disease donors | 5 CpGs | ELOVL2, C1orf132, KLF14, FHL2, TRIM59 | Pyrosequencing/ 1-2 μg | ANN | MAE 3.8 (healthy); 4.4–7.1 (disease) |
Polish | Blood and bloodstains | 2–75 | 303 blood, 45 bloodstains | 2 CpGs | ELOVL2 | Pyrosequencing/ 2 μg | MLRM | 5.03 | |
Huang et al. 2015 | Chinese Han | Blood and bloodstain | 11–70 | 40 blood, 20 bloodstains | 5 CpGs | ASPA, ITGA2B, NPTX2, | Pyrosequencing/ 100 ng | MRLM | 7.87 |
Thong et al. 2017 | Singapore | Blood, bloodstain | 3–80 | 145 blood, 26 bloodstains | 32 CpGs | ELOVL2, FHL2, KLF14, TRIM59, C1orf132 | Pyrosequencing/ 500 ng blood, 50 ng bloodstain | MLRM | 4.8 |
Peng et al. 2019 | Chinese Han | Bloodstains | 21–66 | 99 males | 9 CpGs | TRIM59, RASSF5, C1orf132, chr10:22334463/65, PDE4C, CCDC102B, ELOVL2 | EpiTYPER/ 1 μg | MLRM | 2.94 < MAD <3.55 |
Lee et al. 2015 | Korean | Semen | 20–73 | 31 males | 3 CpGs | TTC7B, NOX4, cg12837463 (no gene associated) | SNaPshot/ 200 ng | MLRM | 4.2 |
Li et al. 2017 | Chinese Han | Semen | 21–54 | 38 males | 1 CpGs | NOX4 | Pyrosequencing/ 500 ng | MLRM | 4.08 |
Lee et al. 2018 | Korean | Semen | 24–57 | 19 forensic case | 1 CpGs | NOX4 | SNaPshot, Multiplex PCR/ 100 ng | MLRM | 4.8 |
Eipel et al. 2016 | Germany | Buccal swab | 1–85 | 55 healthy donors | 3 CpGs | PDE4C, ASPA, ITGA2B | Pyrosequencing/ 500 ng | MLRM | 4.3 |
Buccal swab | 1–85 | 55 healthy donors | 1 CpGs | PDE4C | Pyrosequencing/ 500 ng | MLRM | 5.2 | ||
Belgium | Buccal swab | 0–73 | 50 paternity cases | 8 CpGs | ASPA, PDE4C, ELOVL2, EDARADD | Pyrosequencing/ NA | MQDRM | 3.32 | |
Giuliani et al. 2016 | NA | Teeth (cementum, dentin, dental pulp) | 17–77 | 22 anonymous healthy extracted teeth | 32 CpGs | ELOVL2, FHL2, PENK | EpiTYPER/ 200 ng | MLRM | 1.2–7.07‡ |
Hong et al. 2017 | Korean | Saliva | 18–73 | 226 male females | 6 CpGs | SST, CNGA3, KLF14, TSSK6, TBR1, SLC12A5, (PTPN7) | SNaPshot/ 5-50 ng | MLRM | 3.13 |
Hong et al. 2019 | Korean | Saliva | 18–65 | 95 male females | 7 CpGs | PTPN7, SST, CNGA3, KLF14, TSSK6, TBR1, SLC12A5, | MPS, SNaPshot/ 200 ng | MLRM, NN | 3.69 (MLRM); 3.19 (NN) |
Belgium | Blood | 0–91 | 169 deceased 37, living-donor male females | 4 CpGs | ASPA, PDE4C, ELOVL2, EDARADD | Pyrosequencing/ 200 ng | MQDRM | 3.75 | |
Teeth (Dentin) | 19–70 | 29 extracted teeth male females | 7 CpGs | PDE4C, ELOVL2, EDARADD | Pyrosequencing/ 200 ng | MQDRM | 4.84 | ||
Vidaki et al. 2017 | NA | Blood and saliva | 11–76 | 46 blood, 265 saliva | 16 CpGs | CSNK1D, C21orf63, CASC4, SSRP1, FXN, P2RXL1, RASSF5, ERG, TRIP10, FZD9, KLF14, NR2F2, VGF, NHLRC1, SCGN, C19orf30 | NGS/ 500 ng | MLRM, GRNN | MAE 7.45 (blood); 3.18 (saliva) |
Alghanim et al. 2017 | NA | Blood and saliva | 5–72 | 40 blood, 52 saliva | 27 CpGs | KLF14, SCGN, DLX5 | Pyrosequencing/ 200-500 ng | MLRM | 6.6 (blood); 5.8–6.2 (saliva) |
Hamano et al. 2017 | Japanese | Saliva, cigarette butts | 1–73 | 197 healthy individuals, 16 cigarettes butts | 2 CpGs | ELOVL2, EDARADD | MS-HRM/ NA | SVRM | 5.96 (saliva); 7.65 (cigarette butts) |
Aliferi et al. 2018 | NA | Whole blood, saliva, semen | 11–93 | 76 blood, 34 saliva | 12 CpGs | VGF, TRIP10, KLF14, CSNK1D, FZD9, C21orf63, SSRP1, NHLRC1, ERG, FXN, P2RXL1, SCGN | MPS, Sequencing (MiSeq)/ 50 ng | GRNN, R-models | MAE 4.0 (blood); 7.3 (saliva) |
Richards et al. 2019 | Australian | Blood, semen | 22–84 | 28 samples | 10-31 CpGs | ELOVL2, CCDC102B, PDE4C | MPS/ 200 ng | MLRM | 3.26 (blood); 4.10 (semen) |
Jung et al. 2019 | Korean | Blood, saliva, buccal swabs | 18–74 | 304 healthy donors | 5 CpGs | ELOVL2, FHL2, KLF14, C1orf132/MIR29B2C, TRIM59 | SNaPshot/ 40-200 ng | MLRM | 3.48 (blood); 3.55 (saliva); 4.29 (buccal swab) |